Medigene AG
MDG1
株式のランク
#35337
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
株価
$0.14942078
最終同期: 2025-05-15
時価総額
$3.86M
変化（1日）
0.10%
変化（1年）
39.97%
国
DE
取引 Medigene AG (MDG1)
カテゴリー
Healthcare
Medigene AG（MDG1）の配当利回りの履歴
Medigene AG（銘柄コード: MDG1）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
過去5年間の平均配当利回り: 0.00%
Medigene AG（MDG1）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
| 年 | 配当利回り | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
類似企業または競合他社の配当利回り（TTM）
| 企業 | 配当利回り | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
